What do systematic reviews say?

Pre‐emptive medication vs prophylaxis

• Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 693 participants
  Low

Pre‐emptive medication for cytomegalovirus (CMV) viraemia vs placebo/no treatment

• Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 185 participants
  Low

Ganciclovir vs aciclovir

Ganciclovir showed no clear difference in acute rejection compared with aciclovir (high certainty).

• Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
  RR 0.98 [0.87, 1.1]
  6 studies · 1009 participants
  High

Valaciclovir vs ganciclovir or valganciclovir

It is very uncertain whether valaciclovir changes acute rejection compared with ganciclovir or valganciclovir (very low certainty).

• Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
  RR 0.91 [0.22, 3.73]
  3 studies · 271 participants
  Very low

Extended vs short‐duration valganciclovir

Extended probably leads to lower acute rejection compared with short‐duration valganciclovir (moderate certainty).

• Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
  RR 0.64 [0.43, 0.95]
  2 studies · 454 participants
  Moderate

Low vs standard dose valganciclovir

Low showed no clear difference in acute rejection compared with standard dose valganciclovir (low certainty).

• Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
  RR 0.33 [0.07, 1.61]
  1 study · 196 participants
  Low

Maribavir vs ganciclovir

Maribavir showed no clear difference in acute rejection compared with ganciclovir (low certainty).

• Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
  RR 0.92 [0.53, 1.61]
  1 study · 303 participants
  Low

Antiviral prophylaxis vs placebo or no treatment

Antiviral prophylaxis showed no clear difference in acute rejection compared with placebo or no treatment (high certainty).

• Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
  RR 0.9 [0.78, 1.05]
  13 studies · 1420 participants
  High